Sep 10, 2020
|
Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals
|
|
Sep 10, 2020
|
The Vertex Foundation Announces €1 Million Donation to Ronald McDonald House Charities at the New Children’s Hospital in Ireland
|
|
Sep 01, 2020
|
FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR Mutations
|
|
Aug 21, 2020
|
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older
|
|
Jul 30, 2020
|
Vertex Reports Second-Quarter 2020 Financial Results
|
|
Jul 20, 2020
|
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
|
|
Jul 20, 2020
|
Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation
|
|
Jul 16, 2020
|
Vertex to Announce Second-Quarter 2020 Financial Results on July 30
|
|
Jun 30, 2020
|
Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)
|
|
Jun 26, 2020
|
CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes
|
|
Jun 25, 2020
|
Vertex and the Vertex Foundation Commit $4 Million to Support Racial Equity and Social Justice
|
|
Jun 15, 2020
|
The Vertex Foundation Announces Donation to ARCAH to Help With COVID-19 Response
|
|
Jun 15, 2020
|
The Vertex Foundation Announces Donation to Tafel Deutschland to Help With COVID-19 Response
|
|
Jun 12, 2020
|
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress
|
|
Jun 10, 2020
|
Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene
|
|
Jun 03, 2020
|
Vertex Appoints Diana McKenzie to its Board of Directors
|
|
May 14, 2020
|
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
|
|
May 11, 2020
|
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies
|
|
May 11, 2020
|
Vertex Foundation to Donate 10,000 Meals for Front-Line COVID-19 Health Care Workers at Two Boston Hospitals This Week
|
|
May 01, 2020
|
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene
|
|